Cargando…

Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients

INTRODUCTION: The aim of this nationwide, prospective post-marketing surveillance was to assess the safety and effectiveness of up to 52 weeks of adalimumab treatment in patients with noninfectious intermediate, posterior, or panuveitis in Japanese clinical practice. METHODS: This post-marketing sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Namba, Kenichi, Kaburaki, Toshikatsu, Tsuruga, Hidekazu, Ogawa, Yohei, Iwashita, Eri, Goto, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114192/
https://www.ncbi.nlm.nih.gov/pubmed/35305254
http://dx.doi.org/10.1007/s40123-022-00493-z
_version_ 1784709726833999872
author Namba, Kenichi
Kaburaki, Toshikatsu
Tsuruga, Hidekazu
Ogawa, Yohei
Iwashita, Eri
Goto, Hiroshi
author_facet Namba, Kenichi
Kaburaki, Toshikatsu
Tsuruga, Hidekazu
Ogawa, Yohei
Iwashita, Eri
Goto, Hiroshi
author_sort Namba, Kenichi
collection PubMed
description INTRODUCTION: The aim of this nationwide, prospective post-marketing surveillance was to assess the safety and effectiveness of up to 52 weeks of adalimumab treatment in patients with noninfectious intermediate, posterior, or panuveitis in Japanese clinical practice. METHODS: This post-marketing surveillance was conducted at 60 medical facilities in Japan from October 2016 to June 2020. Patients with noninfectious intermediate, posterior, or panuveitis who were administered adalimumab (Humira(®), AbbVie Inc.) for the first time were eligible. Subcutaneous adalimumab was initially administered at 80 mg, followed by 40 mg 1 week later, then 40 mg every 2 weeks. Safety measures included the incidence of adverse events (AEs) and adverse drug reactions (ADRs; primary endpoint). Effectiveness measures included visual acuity, anterior chamber cell grade, vitreous haze, macular edema, foveal retinal thickness, uveitis recurrence rate, and oral corticosteroid dose. Health-related quality of life was evaluated using the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). RESULTS: During 52 weeks of surveillance, AEs and ADRs occurred in 70 (27.9%) and 47 (18.7%) of 251 patients, respectively. The most common ADR was infection (21/251 patients; 8.4%), including serious infections in eight (3.2%) patients. ADRs were more frequent in patients ≥ 65 years of age, those with concurrent diseases, and those with past medical history. Four patients developed tuberculosis. The uveitis recurrence rate was 24.8% (61/246 patients). All effectiveness measures tended to improve from baseline to week 52, and mean corticosteroid doses decreased. Clinically meaningful changes were observed for most VFQ-25 subscales. CONCLUSIONS: The safety profile of adalimumab was generally consistent with previous reports, and no new safety concerns were identified. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02916017. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-022-00493-z.
format Online
Article
Text
id pubmed-9114192
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-91141922022-05-19 Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients Namba, Kenichi Kaburaki, Toshikatsu Tsuruga, Hidekazu Ogawa, Yohei Iwashita, Eri Goto, Hiroshi Ophthalmol Ther Original Research INTRODUCTION: The aim of this nationwide, prospective post-marketing surveillance was to assess the safety and effectiveness of up to 52 weeks of adalimumab treatment in patients with noninfectious intermediate, posterior, or panuveitis in Japanese clinical practice. METHODS: This post-marketing surveillance was conducted at 60 medical facilities in Japan from October 2016 to June 2020. Patients with noninfectious intermediate, posterior, or panuveitis who were administered adalimumab (Humira(®), AbbVie Inc.) for the first time were eligible. Subcutaneous adalimumab was initially administered at 80 mg, followed by 40 mg 1 week later, then 40 mg every 2 weeks. Safety measures included the incidence of adverse events (AEs) and adverse drug reactions (ADRs; primary endpoint). Effectiveness measures included visual acuity, anterior chamber cell grade, vitreous haze, macular edema, foveal retinal thickness, uveitis recurrence rate, and oral corticosteroid dose. Health-related quality of life was evaluated using the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). RESULTS: During 52 weeks of surveillance, AEs and ADRs occurred in 70 (27.9%) and 47 (18.7%) of 251 patients, respectively. The most common ADR was infection (21/251 patients; 8.4%), including serious infections in eight (3.2%) patients. ADRs were more frequent in patients ≥ 65 years of age, those with concurrent diseases, and those with past medical history. Four patients developed tuberculosis. The uveitis recurrence rate was 24.8% (61/246 patients). All effectiveness measures tended to improve from baseline to week 52, and mean corticosteroid doses decreased. Clinically meaningful changes were observed for most VFQ-25 subscales. CONCLUSIONS: The safety profile of adalimumab was generally consistent with previous reports, and no new safety concerns were identified. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02916017. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-022-00493-z. Springer Healthcare 2022-03-19 2022-06 /pmc/articles/PMC9114192/ /pubmed/35305254 http://dx.doi.org/10.1007/s40123-022-00493-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Namba, Kenichi
Kaburaki, Toshikatsu
Tsuruga, Hidekazu
Ogawa, Yohei
Iwashita, Eri
Goto, Hiroshi
Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients
title Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients
title_full Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients
title_fullStr Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients
title_full_unstemmed Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients
title_short Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis: Post-Marketing Surveillance of 251 Patients
title_sort long-term safety and effectiveness of adalimumab in japanese patients with noninfectious intermediate, posterior, or panuveitis: post-marketing surveillance of 251 patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114192/
https://www.ncbi.nlm.nih.gov/pubmed/35305254
http://dx.doi.org/10.1007/s40123-022-00493-z
work_keys_str_mv AT nambakenichi longtermsafetyandeffectivenessofadalimumabinjapanesepatientswithnoninfectiousintermediateposteriororpanuveitispostmarketingsurveillanceof251patients
AT kaburakitoshikatsu longtermsafetyandeffectivenessofadalimumabinjapanesepatientswithnoninfectiousintermediateposteriororpanuveitispostmarketingsurveillanceof251patients
AT tsurugahidekazu longtermsafetyandeffectivenessofadalimumabinjapanesepatientswithnoninfectiousintermediateposteriororpanuveitispostmarketingsurveillanceof251patients
AT ogawayohei longtermsafetyandeffectivenessofadalimumabinjapanesepatientswithnoninfectiousintermediateposteriororpanuveitispostmarketingsurveillanceof251patients
AT iwashitaeri longtermsafetyandeffectivenessofadalimumabinjapanesepatientswithnoninfectiousintermediateposteriororpanuveitispostmarketingsurveillanceof251patients
AT gotohiroshi longtermsafetyandeffectivenessofadalimumabinjapanesepatientswithnoninfectiousintermediateposteriororpanuveitispostmarketingsurveillanceof251patients